Genomas, Inc.
Records under this name other than patents Genomas, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Showing 1 to 5 of 5 · Back to Genomas, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,558,320 | Physiogenomic method for predicting drug metabolism reserve for antidepressants and stimulants Lapsed on the fee record Ended Jan 31, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jan 31, 2021 | From the USPTO record |
| US 8,012,718 | Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs Lapsed on the fee record Ended Sep 6, 2019 · From the USPTO record | Lapsed on the fee record | Ended Sep 6, 2019 | From the USPTO record |
| US 7,747,392 | Physiogenomic method for predicting clinical outcomes of treatments in patients Lapsed on the fee record Ended Jun 29, 2018 · From the USPTO record | Lapsed on the fee record | Ended Jun 29, 2018 | From the USPTO record |
| US 8,476,012 | Physiogenomic method for predicting metabolic and cardiovascular side effects of thiazolidinediones Lapsed on the fee record Ended Jul 2, 2017 · From the USPTO record | Lapsed on the fee record | Ended Jul 2, 2017 | From the USPTO record |
| US 8,389,247 | Physiogenomic method for predicting diabetes and metabolic syndromes induced by psychotropic drugs Lapsed on the fee record Ended Mar 5, 2017 · From the USPTO record | Lapsed on the fee record | Ended Mar 5, 2017 | From the USPTO record |